2019-2023 In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends

- How will the future reimbursement changes affect individual market segments?

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export?

- How will the future technological advances affect the major market segments?

- Which companies will enter the market and which will not survive?

These and other key strategic issues facing decision-makers are explored in this thought-provoking and multi-faceted portrait of the future U.S. in vitro diagnostics market.

This invaluable strategic planning resource is designed to help corporate, marketing and R&D executives develop effective business plans that best accommodate uncertainties ahead. The report evaluates emerging markets and technologies that may present unexpected threats or offer opportunities; identifies key strategic decisions that will have to be made in the future; and enhances corporate ability to develop realistic contingency plans.

The report presents strategic overview of the U.S. in vitro diagnostics market, including major regulatory, economic, demographic and social trends with potentially significant impact; as well as five- and ten-year test volume and sales forecasts for major testing locations (hospitals, commercial labs, physician offices, blood centers, POC sites, and others) and laboratory disciplines (blood banking, clinical chemistry, immunodiagnostics, coagulation, hematology, flow cytometry, histology, cytology, microbiology, serology, urinalysis and others).

I. Executive Summary
2. Conclusions and Recommendations
3. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Hospitals
f. Admissions
g. Length of Stay
h. Industry Diversification
i. Physician Demographics
j. Aging Population
- More Chronic Illnesses
- Higher Incidence of Disease
- Greater Susceptibility to Iatrogenesis
- More Cases with Multiple Illnesses
4. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. FDA Reform
c. Hospitals
d. Commercial Laboratories
e. Physician Offices
f. Point-of-Care Testing
g. Personal Testing
h. Other Testing Locations
5. Strategic Implications
a. Testing Patterns
- Test Utilization
- Pre-Admission Testing
- Inpatient Testing
- Outpatient Testing
6. Market Segments
a. Clinical Chemistry and Immunodiagnostics
- Introduction
- Future Situation
b. Microbiology and Serology
- Introduction
- Future Situation
c. Hematology and Flow Cytometry
- Introduction
- Future Situation
d. Blood Banking
- Introduction
- Future Situation
e. Histology and Cytology
- Introduction
- Future Situation
f. Coagulation
- Introduction
- Future Situation
g. Urinalysis
- Introduction
- Future Situation
7. Technologies
a. Molecular Diagnostics
- Introduction
- Future Situation
b. Monoclonal Antibodies
- Introduction
- Future Situation
c. Solid Phase Chemistry
- Introduction
- Future Situation
d. Biosensors and Biochips
- Introduction
- Future Situation
e. Automation and Robotics
- Introduction
- Future Situation
f. IT
- Introduction
- Future Situation
8. The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Venture, Merger, and Licensing Activity
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?

List Of Tables

Executive Summary Table: Growth Areas in Clinical Laboratory Testing
Table-1: Estimated U.S. Health Care Expenditures By Type
Table-2: Health Plan Enrollment Distribution
Table-3: Selected Hospital Statistics
Table-4: Total Population And Physician Demographics
Table-5: Test Volume By Location
Table-6: Test Distribution By Location
Table-7: Market Size By Location
Table-8: Typical Pre-Admission Tests
Table-9: Test Volume By Laboratory Discipline
Table-10: Market Size By Laboratory Discipline

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available